Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Sint-Martens-Latem – page 26

1 432 clinical trials in Sint-Martens-Latem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Sint-Martens-Latem at a glance
1 432
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 432 trials in Sint-Martens-Latem

Open in trial search

Study of ENTR-601-44 in Children with Duchenne Muscular Dystrophy Who Are Eligible for Exon 44 Skipping Treatment

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:ENTR-601-44
  • Sponsor:Entrada Therapeutics Inc.

Study of L-Annamycin and Cytarabine for Adults with Refractory or Relapsed Acute Myeloid Leukemia

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Annamycin
  • Sponsor:Moleculin Biotech Inc.

Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Daiichi Sankyo Inc.

Alagille syndrome+1

Recruiting

Study on Long-Term Safety and Effects of Maralixibat for Patients with Alagille Syndrome

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Maralixibat
  • Sponsor:Mirum Pharmaceuticals Inc.

Study on High-Dose Short-Course Antibiotics for Critically Ill Patients with Pneumonia, Intra-Abdominal, or Bloodstream Infections: Ceftriaxone, Linezolid, and Cefotaxime

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cefotaxime
  • Sponsor:Universitair Ziekenhuis Gent

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on the Effectiveness of Lisaftoclax and Azacitidine in Adults with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Ascentage Pharma Group Inc.

Study Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.

Study Comparing Duvelisib with Gemcitabine or Bendamustine for Patients with Relapsed or Resistant T Cell Lymphoma Originating from T Follicular Helper Cells

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Duvelisib
  • Sponsor:Secura Bio Limited

Study of ABBV-400 and Budigalimab for Adults with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effectiveness and Safety of Sepofarsen for Patients with Leber Congenital Amaurosis Due to a Specific Genetic Mutation

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sepofarsen
  • Sponsor:Laboratoires Thea

Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Sint-Martens-Latem

What the registry says about research in the country

01 Musculoskeletal Diseases

Clinical research in Sint-Martens-Latem is focused on musculoskeletal diseases, with a strong emphasis on osteoarthritis and related joint pain. The studies are designed to better understand treatment options that may improve comfort and day-to-day function.

  • Knee osteoarthritis
  • Osteoarthritis
  • Testing new approaches to ease joint pain and support mobility

These trials aim to assess whether emerging therapies can offer meaningful relief for people living with chronic joint disease.

02 Nutritional and Metabolic Diseases

Another active area is nutritional and metabolic diseases, especially studies involving overweight and obesity. Research here is exploring whether new treatments can help with weight management while also addressing related health concerns.

  • Overweight or obesity
  • Evaluating therapies that may support healthier body weight
  • Looking at how metabolic treatment options may affect symptoms linked to joint disease

In addition to weight-related outcomes, the research also considers how these approaches may influence overall well-being in people with overlapping conditions.

03 Combined Osteoarthritis and Weight-Related Research

The clinical trial landscape also brings together osteoarthritis and obesity research, reflecting the close connection between excess body weight and knee pain. This combined focus is especially relevant for patients whose symptoms are affected by both joint and metabolic factors.

  • Knee osteoarthritis with overweight or obesity
  • Measuring changes in pain and physical comfort
  • Assessing whether a new therapy can support both symptom relief and weight-related outcomes

These studies aim to generate practical evidence on treatments that may address more than one aspect of the condition at the same time.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.